Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement
High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease
Qu Biologics Discovers that Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn’s Disease
Qu Biologics Discovers Correlation Between Patient Genetics and Response to Immunotherapy in Inflammatory Bowel Disease
Qu Biologics Announces Initial Results in Randomized, Placebo-Controlled Crohn’s Disease Clinical Trial
Affecting more than 100,000 Canadians, Crohn’s disease is a type of inflammatory bowel disease that causes a range of debilitating symptoms including abdominal pain, diarrhea, vomiting and weight loss. Crohn’s disease is one of a number of autoimmune diseases and cancers that are marked by chronic inflammation within a specific organ or tissue.